中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (10): 935-947.doi: 10.35541/cjd.20260087
中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中华预防医学会皮肤病与性病预防与控制专业委员会
收稿日期:2026-02-11
修回日期:2026-09-10
发布日期:2026-10-07
通讯作者:
周平玉;徐金华;王千秋
E-mail:zpyls@yahoo.com
基金资助:Chinese Society of Dermatology; China Dermatologist Association; Chinese Preventive Medicine Association Professional Committee on Prevention and Control of Dermatology and Sexually Transmitted Diseases
Received:2026-02-11
Revised:2026-09-10
Published:2026-10-07
Contact:
Zhou Pingyu; Xu Jinhua; Wang Qianqiu
E-mail:zpyls@yahoo.com
Supported by:摘要: 【摘要】 神经梅毒是梅毒螺旋体侵犯中枢神经系统引发的一类表现复杂多样的临床综合征,早期诊断困难,晚期常造成不可逆神经损伤,因此临床亟需规范化的诊疗路径。为此,中华医学会皮肤性病学分会、中国医师协会皮肤科医师分会、中华预防医学会皮肤病与性病预防与控制专业委员会联合组织国内性传播疾病及相关领域专家,制订本指南。本指南在借鉴临床实践指南研究与评价工具/推荐分级的评估、制定与评价国际标准的基础上制订,结合我国流行病学特征,重点围绕神经梅毒诊断、治疗和管理中的核心问题展开,涵盖诊断分型、鉴别诊断、并发症处理及多学科协作等方面,旨在为临床提供标准化的诊疗路径,提升神经梅毒早期识别与规范管理的水平。
中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中华预防医学会皮肤病与性病预防与控制专业委员会. 中国神经梅毒诊疗指南(2026版)[J]. 中华皮肤科杂志, 2026,59(10):935-947. doi:10.35541/cjd.20260087
Chinese Society of Dermatology, China Dermatologist Association, Chinese Preventive Medicine Association Professional Committee on Prevention and Control of Dermatology and Sexually Transmitted Diseases. Chinese guidelines for the diagnosis and treatment of neurosyphilis (2026 edition)[J]. Chinese Journal of Dermatology, 2026, 59(10): 935-947.doi:10.35541/cjd.20260087
| [1] | Yang Y, Gu X, Zhu L, et al. Clinical spectrum of late symptomatic neurosyphilis in China: an 11⁃year retrospective study[J]. Sex Transm Infect, 2024,100(8):477⁃483. DOI: 10. 1136/sextrans⁃2024⁃056117. |
| [2] | Gu X, Gao Y, Yan Y, et al. The importance of proper and prompt treatment of ocular syphilis: a lesson from permanent vision loss in 52 eyes[J]. J Eur Acad Dermatol Venereol, 2020,34(7):1569⁃1578. DOI: 10.1111/jdv.16347. |
| [3] | Zhou J, Zhang H, Tang K, et al. An updated review of recent advances in neurosyphilis[J]. Front Med (Lausanne), 2022,9:800383. DOI: 10.3389/fmed.2022.800383. |
| [4] | Shi M, Peng RR, Gao Z, et al. Risk profiles of neurosyphilis in HIV⁃negative patients with primary, secondary and latent syphilis: implications for clinical intervention[J]. J Eur Acad Dermatol Venereol, 2016,30(4):659⁃666. DOI: 10.1111/jdv. 13514. |
| [5] | 中国医师协会皮肤科医师分会性传播疾病专业委员会. 梅毒血清固定临床管理专家共识(2023)[J]. 中华皮肤科杂志, 2023,56(5):383⁃388. DOI: 10.35541/cjd.20220656. |
| [6] | Klein M, Angstwurm K, Esser S, et al. German guidelines on the diagnosis and treatment of neurosyphilis[J]. Neurol Res Pract, 2020,2:33. DOI: 10.1186/s42466⁃020⁃00081⁃1. |
| [7] | Centers For Disease Control And Prevention. Sexually transmitted infections treatment guidelines, 2021[EB/OL].(2021⁃07⁃23)[2024⁃10⁃27]. https://www.cdc.gov/std/treatment⁃guidelines/STI⁃Guidelines⁃2021.pdf. |
| [8] | 王千秋, 刘全忠, 徐金华, 等. 性传播疾病临床诊疗与防治指南[M]. 2版.上海: 上海科学技术出版社, 2020:78⁃100. |
| [9] | Zhu L, Gu X, Peng RR, et al. Comparison of the cerebrospinal fluid (CSF) toluidine red unheated serum test and the CSF rapid plasma reagin test with the CSF venereal disease research laboratory test for diagnosis of neurosyphilis among HIV⁃negative syphilis patients in China[J]. J Clin Microbiol, 2014,52(3):736⁃740. DOI: 10.1128/JCM.02522⁃13. |
| [10] | Guarner J, Jost H, Pillay A, et al. Evaluation of treponemal serum tests performed on cerebrospinal fluid for diagnosis of neurosyphilis[J]. Am J Clin Pathol, 2015,143(4):479⁃484. DOI: 10.1309/AJCPWSL3G8RXMCQR. |
| [11] | Callado GY, Pardo I, Gutfreund MC, et al. Insights into treatment alternatives for neurosyphilis: systematic literature review and meta⁃analysis[J]. Sex Transm Dis, 2024,51(10):641⁃647. DOI: 10.1097/OLQ.0000000000001983. |
| [12] | Marra CM, Ghanem KG. Centers for Disease Control and Prevention Syphilis Summit: difficult clinical and patient management issues[J]. Sex Transm Dis, 2018,45(9S):S10⁃S12. DOI: 10.1097/OLQ.0000000000000851. |
| [13] | Tuddenham S, Ghanem KG. Neurosyphilis: knowledge gaps and controversies[J]. Sex Transm Dis, 2018,45(3):147⁃151. DOI: 10.1097/OLQ.0000000000000723. |
| [14] | Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting, and evaluation in health care[J]. Prev Med, 2010,51(5):421⁃424. DOI: 10.1016/j.ypmed.2010.08.005. |
| [15] | WHO. WHO handbook for guideline development[M]. 2nd ed. Geneva: WHO, 2014:1⁃13,15⁃22. |
| [16] | Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008,336(7650):924⁃926. DOI: 10.1136/bmj.39489.470347.AD. |
| [17] | Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. introduction⁃GRADE evidence profiles and summary of findings tables[J]. J Clin Epidemiol, 2011,64(4):383⁃394. DOI: 10. 1016/j.jclinepi.2010.04.026. |
| [18] | Yang N, Liu H, Zhao W, et al. Development of the Scientific, Transparent and Applicable Rankings (STAR) tool for clinical practice guidelines[J]. Chin Med J (Engl), 2023,136(12):1430⁃1438. DOI: 10.1097/CM9.0000000000002713. |
| [19] | Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies[J]. J Clin Epidemiol, 2014,67(4):401⁃409. DOI: 10.1016/j.jclinepi.2013.12.002. |
| [20] | O'Leary PA, Cole HN, Moore JE, et al. Cooperative clinical studies in the treatment of syphilis: asymptomatic neurosyphilis[J]. Arch Derm Syphilol, 1937, 35(3):387⁃401. DOI: 10.1001/archderm.1937.01470210013002. |
| [21] | Ramachandran PS, Baird RW, Markey P, et al. Neurosyphilis: still prevalent and overlooked in an at risk population[J]. PLoS One, 2020,15(10):e0238617. DOI: 10.1371/journal.pone.0238617. |
| [22] | Solaimalai D, Gupta A, George L, et al. Upward trends of syphilis in the non⁃pregnant adults: a six⁃year report on clinical and epidemiological profile of syphilis from a tertiary care center, India[J]. Front Public Health, 2022,10:908591. DOI: 10.3389/fpubh.2022.908591. |
| [23] | Farahani M, Killian R, Reid GA, et al. Prevalence of syphilis among adults and adolescents in five sub⁃Saharan African countries: findings from Population⁃based HIV Impact Assessment surveys[J]. Lancet Glob Health, 2024,12(9):e1413⁃e1423. DOI: 10.1016/S2214⁃109X(24)00234⁃1. |
| [24] | Du FZ, Zhang HN, Li JJ, et al. Neurosyphilis in China: a systematic review of cases from 2009-2021[J]. Front Med (Lausanne), 2022,9:894841. DOI: 10.3389/fmed.2022.894841. |
| [25] | 陈泽伟, 梁诗晴, 岳晓丽, 等. 2010—2023年中国梅毒流行趋势及时空分布特征[J]. 中华皮肤科杂志, 2024,57(11):1045⁃1050. DOI: 10.35541/cjd.20240073. |
| [26] | Tang W, Huang S, Chen L, et al. Late Neurosyphilis and tertiary syphilis in Guangdong Province, China: results from a cross⁃sectional study[J]. Sci Rep, 2017,7:45339. DOI: 10.1038/srep45339. |
| [27] | Arns B, Vieceli T, Gomes E, et al. Risk factors for neurosyphilis in HIV patients: a retrospective cohort study[J]. Braz J Infect Dis, 2025,29(3):104519. DOI: 10.1016/j.bjid.2025.104519. |
| [28] | Lithgow KV, Church B, Gomez A, et al. Identification of the neuroinvasive pathogen host target, LamR, as an endothelial receptor for the Treponema pallidum adhesin Tp0751[J]. mSphere, 2020,5(2):e00195⁃20. DOI: 10.1128/mSphere.00195⁃20. |
| [29] | Daza⁃Ovalle JF, Ramirez⁃Penuela JA, Ramirez⁃Castro D, et al. Stroke in the setting of neurosyphilis: a comprehensive literature review[J]. Neurohospitalist, 2026,16(1):50⁃60. DOI: 10.1177/19418744251355654. |
| [30] | Wang C, Zhu L, Gao Z, et al. Increased interleukin⁃17 in peripheral blood and cerebrospinal fluid of neurosyphilis patients[J]. PLoS Negl Trop Dis, 2014,8(7):e3004. DOI: 10.1371/journal.pntd.0003004. |
| [31] | Radolf JD, Deka RK, Anand A, et al. Treponema pallidum, the syphilis spirochete: making a living as a stealth pathogen[J]. Nat Rev Microbiol, 2016,14(12):744⁃759. DOI: 10.1038/nrmicro.2016.141. |
| [32] | Li K, Wang C, Lu H, et al. Regulatory T cells in peripheral blood and cerebrospinal fluid of syphilis patients with and without neurological involvement[J]. PLoS Negl Trop Dis, 2013,7(11):e2528. DOI: 10.1371/journal.pntd.0002528. |
| [33] | Yu Q, Cheng Y, Wang Y, et al. Aberrant humoral immune responses in neurosyphilis: CXCL13/CXCR5 play a pivotal role for B⁃cell recruitment to the cerebrospinal fluid[J]. J Infect Dis, 2017,216(5):534⁃544. DOI: 10.1093/infdis/jix233. |
| [34] | Shi M, Long F, Zou D, et al. Evaluation of cerebrospinal fluid Treponema pallidum particle agglutination assay titer for neurosyphilis diagnosis among HIV⁃negative syphilis patients[J]. Front Immunol, 2025,16:1572137. DOI: 10.3389/fimmu. 2025.1572137. |
| [35] | Reiber H. Flow rate of cerebrospinal fluid (CSF)⁃⁃a concept common to normal blood⁃CSF barrier function and to dysfunction in neurological diseases[J]. J Neurol Sci, 1994,122(2):189⁃203. DOI: 10.1016/0022⁃510x(94)90298⁃4. |
| [36] | Reiber H, Peter JB. Cerebrospinal fluid analysis: disease⁃related data patterns and evaluation programs[J]. J Neurol Sci, 2001,184(2):101⁃122. DOI: 10.1016/s0022⁃510x(00)00501⁃3. |
| [37] | Cerny EH, Hambie EA, Lee F, et al. Adenovirus ELISA for the evaluation of cerebrospinal fluid in patients with suspected neurosyphilis[J]. Am J Clin Pathol, 1985,84(4):505⁃508. DOI: 10.1093/ajcp/84.4.505. |
| [38] | van Eijk RV, Wolters EC, Tutuarima JA, et al. Effect of early and late syphilis on central nervous system: cerebrospinal fluid changes and neurological deficit[J]. Genitourin Med, 1987,63(2):77⁃82. DOI: 10.1136/sti.63.2.77. |
| [39] | Kissani N, Nafia S, Zahlane S, et al. Neurosyphilis: a series of 178 cases at the 3rd⁃level hospital of Marrakesh (Morocco)[J]. Eur J Clin Microbiol Infect Dis, 2021,40(10):2129⁃2135. DOI: 10.1007/s10096⁃021⁃04253⁃y. |
| [40] | Patel SS, Blum AL, Morgan RT, et al. Analysis of neurosyphilis imaging methods and treatment: a focused review[J]. Cureus, 2024,16(11):e72976. DOI: 10.7759/cureus.72976. |
| [41] | Choi EK, Kim YD, Jeong H, et al. Imaging characteristics of brain SPECT, PET, and MRI in neurosyphilis[J]. Nucl Med Mol Imaging, 2021,55(1):48⁃51. DOI: 10.1007/s13139⁃021⁃00684⁃9. |
| [42] | Wang C, Hu Z, Zheng X, et al. A new specimen for syphilis diagnosis: evidence by high loads of treponema pallidum DNA in Saliva[J]. Clin Infect Dis, 2021,73(9):e3250⁃e3258. DOI: 10.1093/cid/ciaa1613. |
| [43] | Gayet⁃Ageron A, Lautenschlager S, Ninet B, et al. Sensitivity, specificity and likelihood ratios of PCR in the diagnosis of syphilis: a systematic review and meta⁃analysis[J]. Sex Transm Infect, 2013,89(3):251⁃256. DOI: 10.1136/sextrans⁃2012⁃050622. |
| [44] | Vanhaecke C, Grange P, Benhaddou N, et al. Clinical and biological characteristics of 40 patients with neurosyphilis and evaluation of Treponema pallidum nested polymerase chain reaction in cerebrospinal fluid samples[J]. Clin Infect Dis, 2016,63(9):1180⁃1186. DOI: 10.1093/cid/ciw499. |
| [45] | Dai T, Qu R, Liu J, et al. Efficacy of doxycycline in the treatment of syphilis[J]. Antimicrob Agents Chemother, 2017,61(1)DOI: 10.1128/AAC.01092⁃16. |
| [46] | Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis[J]. Antimicrob Agents Chemother, 1985,28(2):347⁃348. DOI: 10.1128/AAC.28.2.347. |
| [47] | Girometti N, Junejo MH, Nugent D, et al. Clinical and serological outcomes in patients treated with oral doxycycline for early neurosyphilis[J]. J Antimicrob Chemother, 2021,76(7):1916⁃1919. DOI: 10.1093/jac/dkab100. |
| [48] | Kingston M, French P, Higgins S, et al. UK national guidelines on the management of syphilis 2015[J]. Int J STD AIDS, 2016,27(6):421⁃446. DOI: 10.1177/0956462415624059. |
| [49] | Ozturk⁃Engin D, Erdem H, Hasbun R, et al. Predictors of unfavorable outcome in neurosyphilis: multicenter ID⁃IRI study[J]. Eur J Clin Microbiol Infect Dis, 2019,38(1):125⁃134. DOI: 10.1007/s10096⁃018⁃3403⁃7. |
| [50] | Wu YS, Lane HY, Lin CH. Donepezil improved cognitive deficits in a patient with neurosyphilis[J]. Clin Neuropharmacol, 2015,38(4):156⁃157. DOI: 10.1097/WNF.0000000000000094. |
| [51] | Chen WC, Wang HY, Chen PA, et al. Memantine rescues neurosyphilis⁃related schizophrenic⁃like features and cognitive deficit[J]. Clin Neuropharmacol, 2019,42(4):133⁃135. DOI: 10.1097/WNF.0000000000000347. |
| [52] | Hamill MM, Ghanem KG, Tuddenham S. State⁃of⁃the⁃art review: neurosyphilis[J]. Clin Infect Dis, 2024,78(5):e57⁃e68. DOI: 10.1093/cid/ciad437. |
| [53] | Mayoral V, Galvez R, Ferrándiz M, et al. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta⁃analysis of effectiveness and safety[J]. Front Pain Res (Lausanne), 2024,5:1513597. DOI: 10.3389/fpain.2024.1513597. |
| [54] | Swisher CB, Doreswamy M, Gingrich KJ, et al. Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors[J]. Neurocrit Care, 2012,16(1):109⁃113. DOI: 10.1007/s12028⁃011⁃9626⁃4. |
| [55] | Peng RR, Wu J, Zhao W, et al. An observational prospective study based on a large cohort of HIV⁃negative neurosyphilis patients with particular reference to the Jarisch⁃Herxheimer reaction[J]. Eur J Clin Microbiol Infect Dis, 2024,43(6):1073⁃1080. DOI: 10.1007/s10096⁃024⁃04810⁃1. |
| [56] | Public Health Agency of Canada. Syphilis guide: treatment and follow⁃up[EB/OL]. (2026⁃06⁃08)[2026⁃06⁃08]. https://www.canada.ca/en/public⁃health/services/infectious⁃diseases/sexual⁃health⁃sexually⁃transmitted⁃infections/canadian⁃guidelines/syphilis/treatment⁃follow⁃up.html. |
| [1] | 中华医学会皮肤性病学分会 中华医学会变态反应学分会 中国麻风防治协会. [开放获取] 中国药疹诊疗指南(2026版)[J]. 中华皮肤科杂志, 2026, 59(9): 811-826. |
| [2] | 中国医师协会皮肤科医师分会 中华医学会皮肤性病学分会 中国医疗保健国际交流促进会皮肤医学分会 中国罕见病联盟皮肤病学分会 . [开放获取] 斑块状银屑病生物制剂长程治疗管理专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(9): 827-843. |
| [3] | 梁云生. [开放获取] 慢性手部湿疹评估现状及进展[J]. 中华皮肤科杂志, 2026, 59(9): 850-855. |
| [4] | 唐祯 刘宇航 杨凌 胡凌雪 贺治杰 曹凯 丁澍. 反射式共聚焦显微镜在皮肤型红斑狼疮诊断与鉴别诊断中的价值及特征分析[J]. 中华皮肤科杂志, 2026, 59(9): 873-880. |
| [5] | 《西罗莫司治疗卡波西样血管内皮瘤中国专家共识(版)》制订专家组. 西罗莫司治疗卡波西样血管内皮瘤中国专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(8): 728-737. |
| [6] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. 中国皮肤鳞状细胞癌诊疗指南(2026版)[J]. 中华皮肤科杂志, 2026, 59(8): 703-716. |
| [7] | 《脓疱型银屑病诊疗中国专家共识(版)》编写委员会专家组. [开放获取] 脓疱型银屑病诊疗中国专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(8): 717-727. |
| [8] | 李燕红 姜琨 吴卓璇 章建兰 方美珍 刘姝婷 王琳琳 胡磊 周小勇 陈柳青 陈金波. 程序性死亡受体1抑制剂相关皮肤不良反应18例临床资料分析[J]. 中华皮肤科杂志, 2026, 59(8): 783-787. |
| [9] | 魏瑾 闫会文 张建中 伦文辉. 司库奇尤单抗治疗合并人类免疫缺陷病毒感染的中重度斑块状银屑病10例临床疗效观察[J]. 中华皮肤科杂志, 2026, 59(7): 671-674. |
| [10] | 王琳琳 曹立娟 陈柳青 李东升 胡燕燕. 海姆泊芬光动力疗法治疗四肢鲜红斑痣疗效观察及安全性回顾分析[J]. 中华皮肤科杂志, 2026, 59(7): 637-644. |
| [11] | 刘怿菲 金炫沃 刘鹏月 张希萌 吴严. 点阵CO2激光联合A型肉毒毒素外用治疗面部毛孔粗大的半脸自身对照临床试验[J]. 中华皮肤科杂志, 2026, 59(7): 645-653. |
| [12] | 张国龙 赵子君. 氨基酮戊酸光动力疗法治疗皮肤鳞状细胞癌的现状、挑战和思考[J]. 中华皮肤科杂志, 2026, 59(7): 626-631. |
| [13] | 中国研究型医院学会皮肤科学专业委员会 中国医师协会皮肤科医师分会. [开放获取] 窄谱中波紫外线光疗皮肤科临床应用指南(2026版)[J]. 中华皮肤科杂志, 2026, 59(7): 595-610. |
| [14] | 中华医学会皮肤性病学分会光动力治疗研究协作组 中国康复医学会皮肤病康复专业委员会及光动力治疗与康复专业委员会 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 氨基酮戊酸光动力疗法治疗尖锐湿疣的临床应用指南(2026版)[J]. 中华皮肤科杂志, 2026, 59(7): 611-618. |
| [15] | 何庆 张涛 王秀丽 高兴华 陈洪铎 柳敏 齐瑞群. 光线性角化病恶性进展相关生物标志物的研究进展[J]. 中华皮肤科杂志, 2026, 59(7): 687-690. |
|